RIKEN Immune Regenerative Medicine

RIKEN Immune Regenerative Medicine is a Japanese biotechnology company dedicated to the development and commercialization of novel cancer immunotherapies based on technology licensed from RIKEN. The company's core platform involves the activation of Natural Killer T (NKT) cells using alpha-galactosylceramide (alpha-GalCer) pulsed dendritic cells. This approach aims to induce a robust and sustained anti-tumor immune response by bridging the innate and adaptive immune systems. The company is currently advancing clinical programs for various solid tumors, including lung and head and neck cancers, primarily within the Japanese regulatory framework for regenerative medicine. RIKEN Immune Regenerative Medicine operates as a RIKEN-certified venture, maintaining close ties with academic and clinical institutions to advance its pipeline.